Network Contributions / Beiträge zu Netzwerken
ILCCO - International Lung Cancer Consortium
The aim of the consortium is to share comparable data, increase power to detect gene–environment interactions, and focus on special subgroups such as early onset lung cancer cases, non-smokers, or patients with tumours of rare histology. Questionnaire data from a total of 26,000 case-control pairs, and the biological samples from the majority of the subjects are available and genotyping is coordinated across laboratories.
The Institute of Epidemiology participate in this consortium with about 5,000 cases and controls of two lung cancer studies to answer questions on genetic susceptibility, family history and medical condition. ILCCO is an ideal way to maximize study efficiency and overcome the limitations of individual studies.
The LUCY-study brings its genome-wide results of 500 cases and 500 controls into the consortium. The initial focus of ILCCO in 2008 will be an integrated analysis of more than 10,000 genomewide association scans available to the consortium, thereby identifying novel disease-susceptibility variants undetectable in the individual small studies expecially in subgroups. Replication of the meta-analysis results is planned in the ILCCO samples, presumably by coordinated genotyping.
Partners in the ILCCO consortium:
MD Anderson Cancer Center, University of Texas, USA; Fred Hutchinson Cancer Research Center, Seattle, USA; Harvard School of Public Health, Boston, USA; International Agency for Research on Cancer (IARC), Lyon, France; Wayne State University, Detroit, USA; National Cancer Institute, NIH, Bethesda, USA; The University of Liverpool Cancer Research Centre, Liverpool, UK; National Institute of Occupational Health, Oslo, Norway; Samuel Lunenfeld Research Institute, Toronto, Canada; Mayo Clinic, Rochester, USA; Harvard University, Boston, USA; Brown University, Providence, USA; Seoul National University, Seoul, South-Korea; Institute of Cancer Research, Sutton, UK; Penn State College of Medicine, Philadelphia, USA; German Cancer Research Center (DKFZ), Germany; University of Goettingen, Germany; University of Hawaii, Honululu, Hawaii; Cancer Center and Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland; National University of Singapore, Singapore; INSERM, Cedex, France; Pennsylvania State Cancer Institute, Hershey, USA; deCODE Genetics, Reykjavik, Iceland; Russian NN Blokhin Cancer Research Centre, Moskow; Russia; UCLA School of Public Health, Los Angeles, USA; University of California, San Francisco, USA.
Link to Project ILCCO